Morning vs afternoon: can timing boost kidney cancer treatment?

This study looks at whether getting standard immunotherapy drugs (nivolumab and ipilimumab) in the morning or afternoon makes a difference for people with advanced kidney cancer. About 142 adults will be randomly assigned to morning or afternoon infusions. Researchers will track survival, tumor response, and side effects to see if timing affects outcomes.